The latest developments in benumb discovery - including solutions to have a go at portliness, the latest on the Northwick Park dull-pest misfortune and issues adjacent drugs used in sport and the Olympics - commitment be highlighted at a conference in Brighton next week.

The British Pharmacological Group (BPS), Europe’s leading pharmacological research alliance, is to host its Winter Caucus in the seaside resort, attracting experts from across the world.

Running from 16 to 18 December, the three-day seminar force agree the latest research tackling the worldwide weight unmanageable.

Other researchers will present their work on the safety of drugs, particularly the up to date biopharmaceuticals developed in the wake of the Northwick Greensward drug-venture disaster in 2006 that left six volunteers fighting in place of their lives.

A third theme of the talk will assess the latest techniques using stem-cell therapies to outfit callousness disease.

Impotencia sexual masculina

By the skin of one’s teeth three presentations from the stuffed presentation will be press released but newsworthy research to be presented at the Brighton colloquium includes:

  • Professor Luke O’Neill (Trinity College Dublin): ‘The IL-1 receptor / Toll-like receptor super-family: 10 years of progress’

  • Professor O’Neill’s talk will deal with possible new targets for drugs to treat immune and inflammatory diseases.
  • These targets are the Toll-like receptors (TLRs) and they have been identified as possible new targets to block in such diseases as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis and multiple sclerosis.
  • They are also implicated in infectious diseases such as malaria and TB. TLRs have been shown to be over-active in these diseases - they go into overdrive and cause inflammation and damage.
  • There is a consensus emerging that inhibiting them might prove useful to treat these diseases, or, alternatively, if they are activated, they might boost the immune response to help generate new vaccines.
  • In his talk, Professor O’Neill will lay out the case for TLRs as excellent new targets worth exploring for these diseases where there remains a major unmet medical need.
  • He will also describe what to target - his team has found proteins within the Toll-like receptor pathway that might lend themselves to therapeutic manipulation.
  • TLRs may also prove essential in the fight against malaria, as the disease has recently shown resistance to current medication (16 Dec).
    * Dr Sandra Diebold (Cancer Research UK): ‘Stimulatory nucleic acids as adjuvants for tumour immunotherapty’ (16 Dec)
    * Dr Stephen Poole (National Institute for Biological Standards and Controls): ‘Cytokine Storm in the phase 1 trial of monoclonal antibody TGN1412 - better understanding the causes to improve preclinical testing of immunotherapeutics’ (16 Dec)

  • Dr Ben Field (Imperial College, London): ‘New targets - peripheral obesity’ (17 Dec)
  • Dr Nick Finer (Wellcome Clinical Research Facility, Cambridge): ‘Clinical challenges: can current drugs compete with surgery?’ (17 Dec)
  • Dr Christine Mummery (Leiden University Medical Centre, Netherlands): ‘Cardiomyocytes from human embryonic stem cells: towards cell-based therapy and disease models’ (18 Dec)
  • Dr Marisa Jaconi (Geneva University, Switzerland): ‘ Tissue-engineered strategies using biomatrices to implant stem cells into the infarcted heart’ (18 Dec)
  • Dr Kai C. Wollert (Hanover Medical School, Germany): ‘Bone marrow cell therapy after myocardial infarction: the BOOST experience’ (18 Dec)

—————————-
Article adapted by Medical Report Today from original press release.
—————————-

Notes:

Additional lectures:

  • Professor David Back (Liverpool): ‘Optimising the management of patients with HIV infection’ (16 Dec)

  • Dr Andrew Kicman (Kings College London): ‘Pharmacology in sports/Olympics’ (17 Dec)
  • Kirk Leech / Corina Hadjiodysseos: ‘Animal research: Winning the debate’ (18 Dec)
  • Professor Arthur Weston (University of Manchester): Potassium channels and myo-endothelial crosstalk in blood vessels: a pharmacologist’s view’ (18 Dec)

The British Pharmacological Sodality, including its Clinical Pharmacology Department, is the professional association for pharmacologists in the UK and is undivided of the chief pharmacological societies in the beget.

The history of the Upper classes dates back to 1931 when a group of pharmacologists met in Oxford and unconditional to form a learned society. Since those small beginnings the Consociation has grown to about 2,500 members, who hopped in academia, industry and the trim services, and many are medically well-informed. The Society covers the whole spectrum of pharmacology, including the laboratory, clinical and toxicological aspects.

The aims of the Sorority are to sanction and assist pharmacology, including clinical pharmacology, by: assisting, promoting and encouraging research and providing a forum for the giving of pharmacology; publishing the results of research; promoting and encouraging the lore and training of pharmacologists; publishing serious in various forms, and promoting and arranging conferences and meetings.

As a service to further dope not far from the British Pharmacological Society visit: http://www.bps.ac.uk

The BPS Winter Meet will be held at the Hilton Brighton Metropole Hotel from Tuesday, 16 December, to Thursday, 18 December, 2008.

Click here for further information almost the BPS Winter Joining.

Commencement: Aeron Haworth

University of Manchester